NEW YORK, July 20 (Reuters) - Healthcare company Bayer on Friday said it would discontinue the sale of its birth control product Essure in the United States, citing a decline in sales of the ...

A postmarket surveillance study has linked Bayer’s Essure birth-control implant to a numerically higher rate of some safety outcomes than laparoscopic tubal sterilization (LTS). The latest interim ...

The Essure permanent birth control device is set to receive more scrutiny. FDA recently announced that it will convene a September 24 meeting of the Obstetrics and Gynecology Devices Panel of the ...

Bayer, the company that manufactured and marketed the dangerous birth-control device Essure, is looking more and more like a bad actor as the facts unfold. The target of lawsuits filed on behalf of ...

In the latest update in the years-long investigation into the safety of Bayer’s permanent birth control device Essure, the US Food and Drug Administration (FDA) on Friday said that nearly all unused ...

Approximately 39,000 women filed claims saying they were injured by the device, which is a metal coil that is inserted in a fallopian tube. Bayer offices located in San Francisco's Mission Bay ...

Editor's Note: On Wednesday, Focus reported allegations raised by Rep. Mike Fitzpatrick (R-PA) during a press call that Bayer's permanent birth control device Essure is associated with far more ...

The duration of the study will be extended from three years to five, and it will include additional blood testing to track signs of immune responses. (Andrew Harnik, Associated Press) The FDA and ...

Bayer AG has agreed to pay roughly $1.6 billion to settle about 90% of the nearly 39,000 total filed and unfiled claims in the United States against its Essure birth-control device. It is not ...